{"id":"alvac-2-120-b-mn-gnp-vcp1452","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, induration)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2431867","moleculeType":"Small molecule","molecularWeight":"264.32"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This vaccine uses a live attenuated canarypox virus vector to deliver HIV-1 envelope glycoprotein (gp120) and other immunogenic sequences from HIV-1 clades B and MN. The vaccine is designed to stimulate both CD8+ T-cell and antibody responses to prevent or control HIV-1 infection. It was developed as part of the HVTN 702 trial and subsequent HIV vaccine development programs.","oneSentence":"ALVAC(2)120(B,MN)GNP is a recombinant canarypox virus-based vaccine that expresses HIV-1 gp120 and other viral antigens to elicit cellular and humoral immune responses against HIV-1.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:00.776Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 prevention (therapeutic vaccine candidate)"}]},"trialDetails":[{"nctId":"NCT00000904","phase":"PHASE1","title":"Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT00005758","phase":"PHASE3","title":"Effectiveness of Giving an HIV Vaccine (Remune) to HIV-Positive Patients Receiving an Anti-HIV Drug Combination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":472},{"nctId":"NCT00006291","phase":"PHASE2","title":"Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT00011011","phase":"PHASE1, PHASE2","title":"Vaccine (ALVAC-HIV vCP1452) Use and Intermittent Withdrawal of Anti-HIV Drugs in Patients With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-02","conditions":"HIV Infections","enrollment":94},{"nctId":"NCT00006495","phase":"PHASE1","title":"Immune Responses in HIV-Positive Patients Receiving an Anti-HIV Drug Combination When Given the HIV Vaccines Remune and vCP1452","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":80},{"nctId":"NCT00026624","phase":"PHASE1","title":"Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00000879","phase":"PHASE1","title":"A Study of the Effects of Giving Two Anti-HIV Vaccines to Babies of HIV-Positive Mothers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":48},{"nctId":"NCT00007332","phase":"PHASE2","title":"Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":330},{"nctId":"NCT00027261","phase":"PHASE1","title":"Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":110},{"nctId":"NCT00011037","phase":"PHASE2","title":"ALVAC-HIV vCP1452 Alone and Combined With MN rgp120","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, HIV Seronegativity","enrollment":160},{"nctId":"NCT00006509","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of an HIV Vaccine for HIV-Positive Patients Receiving Anti-HIV Drugs for at Least 2 Years","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":12},{"nctId":"NCT00013663","phase":"PHASE2","title":"Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":92}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ALVAC(2)120(B,MN)GNP (vCP1452)","genericName":"ALVAC(2)120(B,MN)GNP (vCP1452)","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Biologic","firstApprovalDate":"","aiSummary":"ALVAC(2)120(B,MN)GNP is a recombinant canarypox virus-based vaccine that expresses HIV-1 gp120 and other viral antigens to elicit cellular and humoral immune responses against HIV-1. Used for HIV-1 prevention (therapeutic vaccine candidate).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}